相关实验视频

Updated: Jun 11, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

截断的补充因子 H Y402 基因疗法治愈 C3 淋巴结膜炎

Lindsey A Chew^1,2, Daniel Grigsby³, C Garren Hester¹

¹Department of Ophthalmology, Duke Eye Center, Duke University Medical Center, Durham, NC 27710.

bioRxiv : the preprint server for biology

|September 30, 2024

概括

腺相关病毒输送截断的补充因子H (tCFH) 有效地逆转了小鼠的C3球球腺炎. 这种基因疗法方法对治疗C3G和与年龄相关的黄斑变性很有前途.

科学领域:

眼科医生眼科眼科
腎臟病學 (nephrology) 是一種醫學專業.
基因治疗基因治疗

背景情况:

与年龄相关的黄斑变性 (AMD) 和C3型血球膜炎 (C3G) 分享补充失调的途径.
目前对C3G的治疗方法有限,以前使用外源补充因子H (CFH) 的尝试面临免疫排斥.
C3G的特点是补充替代途径失调.

研究的目的:

为了研究由腺相关病毒 (AAV) 介导的截断CFH (tCFH) 的传递,用于治疗C3G.
在小鼠模型中评估AAV-tCFH基因治疗的疗效和长期安全性.
探索AAV-tCFH作为C3G和AMD的潜在治疗方法.

主要方法:

使用了C3G.的Cfh/-鼠标模型.
使用各种编码截断补充因子H (tCFH) 的腺相关病毒 (AAV) 载体.
监测补充通路抑制,疾病逆转和免疫反应.

主要成果:

长期的AAV介导的tCFH输送成功抑制了补充替代途径.
在没有免疫排斥的证据的情况下实现了C3G的逆转.
不同的AAV载体表现出不同程度的效率和疗效.

结论:

以AAV为媒介的tCFH基因疗法为C3G治疗提供了一个有前途的策略,克服了以前方法的局限性.
这项研究为AMD的AAV-tCFH基因增强疗法提供了概念证明.
这些发现支持开发针对C3G和AMD患者补体失调的新型基因疗法.

关键词:

在C3型球体隆炎中.在C3型淋巴细胞病变中.与年龄相关的黄斑变性.补充因子 H 是 H 的补充因子.补充法规补充法规的规定.基因替代是一种基因替代.基因治疗的基因疗法

更多相关视频

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

相关概念视频

Gene Therapy

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...